Catherine M. Szyman - 02 Aug 2021 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role: CVP, Critical Care
Signature: Linda J. Park, Attorney-in-Fact
Issuer symbol: EW
Transactions as of: 02 Aug 2021
Net transactions value: -$1,376,504
Form type: 4
Filing time: 02 Aug 2021, 21:35:24 UTC
Previous filing: 15 Jun 2021
Next filing: 05 Aug 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EW	Common Stock	Options Exercise	$326,400	+15,000	+54%	$21.76	42,759	02 Aug 2021	Direct
transaction	EW	Common Stock	Sale	$1,702,904	-15,000	-35%	$113.53	27,759	02 Aug 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EW	Employee Stock Option (Right to Acquire)	Options Exercise	$0	-15,000	-10%	$0.000000	132,882	02 Aug 2021	Common Stock	15,000	$21.76	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was executed in multiple trades at prices ranging from $113.4450 to $113.7500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.